Data comp: How the most-advanced Lp(a) therapies stacked up in Phase II

Three therapies targeting the cardiovascular risk factor lipoprotein(a) have advanced into Phase III trials. While the Phase II data show powerful Lp(a) reduction for all three, durability offers the clearest sign of differentiation.

Concentrations of the cholesterol-carrying particle Lp(a) in the bloodstream are largely under genetic control, with diet having little impact. Genetic variants in the particle’s apolipoprotein(a) component lead to high levels of circulating Lp(a) and predispose patients to atherosclerotic cardiovascular disease (ASCVD), making the lipoprotein a prime target for new therapeutics...